MarketBeat Week in Review – 02/03 – 02/07 Teva Pharmaceutical Industries (NYSE:TEVA) reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were largely offset by growth in its…
novative medicines portfolio. Chief Executive Officer Richard Francis said Teva’s growth strategy is increasingly being driven by AUSTEDO, AJOVY and UZEDY, whose combined revenue rose 43% year over year during the quarter
The company raised its full-year revenue outlook for all three products and increased the midpoint of its overall 2026 revenue guidance by $75 million. Innovative portfolio drives guidance increases – Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now AUSTEDO, Teva’s treatment for tardive dyskinesia and Huntington’s disease chorea, generated $676 million in U.S. revenue during the quarter, up 33% year over year. Global revenue increased 40%, supported by a 14% increase in total prescriptions and 21% growth in milligrams dispensed, Francis said.
AUSTEDO XR accounted for more than 60% of new AUSTEDO patient starts. Teva raised AUSTEDO’s 2026 revenue guidance to a range of $2.45 billion to $2.6 billion, an increase of $50 million at the midpoint. Francis said the midpoint of the revised range reaches the company’s previously stated 2027 target of $2.5 billion and reiterated Teva’s expectation for more than $3 billion in peak sales. – 2 Generic Drug Stocks Ready to Surge in 2025 UZEDY, a long-acting injectable treatment for schizophrenia, posted quarterly revenue of $77 million, up 43% from a year earlier.